Economic impact of hypoglycemia on healthcare in Spain

References

• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemia. Nature414, 782–787 (2001).
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trials Research Group. The effect of intensive treatment of diabetes on the development and progression long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329, 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Effects of intensive blood glucose control on vascular outcomes in patients with Type 2 diabetes mellitus: results of the ADVANCE trial. N. Engl. J. Med.358, 2560–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trials Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes46, 271–286 (1997).
   PubMed Web of Science ®Google Scholar
• UK Hypoglycemia Study Group. Risk of hypoglycaemia in Types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia50, 1140–1147 (2007).
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Cryer PE, Axelrod L, Grossman AB et al. Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metabol.94, 709–728 (2009).
   PubMed Web of Science ®Google Scholar
• González P, Fauré E, del Castillo A. Coste de la diabetes mellitus en España. Med. Clin.127(20), 776–784 (2006).
   PubMed Web of Science ®Google Scholar
• Leese GP, Wang J, Bromhall J. Frequency of severe hypoglycaemia requiring emergency treatment in Type 1 and Type 2 diabetes: a population-based study of health service resource use. Diabetes Care26, 1176–1180 (2003).
   PubMed Web of Science ®Google Scholar
• Arroyo J, Badía X, de la Calle H et al. Tratamiento de los pacientes con diabetes mellitus Tipo 2 en Atención Primaria en España. Med. Clin.125, 166–172 (2005).
   PubMed Web of Science ®Google Scholar
• Davies RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in Type 1 and Type 2 diabetes. Curr. Med. Res. Opin.21(9), 1477–1483 (2005).
   PubMedGoogle Scholar
• American Diabetes Association (ADA) workgroup on hypoglycemia. Defining and reporting hypoglycaemia in diabetes. Diabetes Care28, 1245–1249 (2005).
   PubMed Web of Science ®Google Scholar
• Cryer P. The barrier of hypoglycaemia in diabetes. Diabetes57(12), 3169–3176 (2008).
   PubMed Web of Science ®Google Scholar
• Reviriego J, Gomis R, Marañes JP, Ricart W, Hudson P, Sacristán JA. Cost of severe hypoglycaemia in patients with Type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia. Int. J. Clin. Pract.62(7), 1026–1032 (2008).
   PubMed Web of Science ®Google Scholar
• Wright AD, Cull CA, Macleod KM, Holman RR; for the UKPDS Group. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J. Diabetes Complicat.20(6), 395–340 (2006).
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Morris AD, Frier BM et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population based study. Diabetes Med.22(6), 749–755 (2005).
   PubMed Web of Science ®Google Scholar
• Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with Type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care25(2), 330–336 (2002).
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet. Med.25, 245–254 (2008).
   PubMed Web of Science ®Google Scholar
• Fanelli CG, Porcellatti F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size of the problem. Diabetes Metab. Res. Rev.20(Suppl. 2), S32–S42 (2004).
   PubMed Web of Science ®Google Scholar
• Moreno A, Sánchez P, Santiago P, Martinez P, López JA, Arraiga C. Unawareness hypoglycaemia in Type 1 diabetes. Avances en Diabetologia25, 491–493 (2009).
   Google Scholar
• Segel SA, Paramote DS, Creyer PE. Hypoglycaemia-associated autonomic failure in advanced Type 2 diabetes. Diabetes51, 724–733 (2002).
   PubMed Web of Science ®Google Scholar
• Smith CB, Choudhary P, Pernet A, Hopkins D, Amiel SA. Hypoglycaemia unawareness is associated with reduced adherence to therapeutic decisions in patients with Type 1 diabetes evidence from a clinical audit. Diabetes Care32, 1513–1517 (2009).
   PubMedGoogle Scholar
• Monereo S, Pavón I, Vega B, Elviro R. Diabetes mellitus: aproximación al coste por proceso aplicado al paciente diabético ingresado. Endocrinología44, 319–325 (1997).
   Google Scholar
• Aguilar M, Carral F, Ortego J, Ballesta M, Olveira G. Costes economicos asociados a la diabetes Tipo 1. Avances en Diabetologia20(Suppl. 1), 56 (2004).
   Google Scholar
• Josson B. Revealing the cost of Type II diabetes in Europe. Diabetologia45, S5–S12 (2002).
   Google Scholar
• Schnell O, Hummel M, Weber C. Economic and clinical aspects of diabetes regarding self-monitoring of blood glucose. Diabetes Technol. Ther.10(Suppl. 1), S72–S81 (2008).
   Web of Science ®Google Scholar
• Oliva J, Lobo F, Molina B, Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care27, 2616–2621 (2004).
   PubMed Web of Science ®Google Scholar
• Mata M, Antoñanzas F, Tafalla M, Sanz P. The cost of Type 2 diabetes in Spain: the CODE-2 study. Gac. Sanit.16(6), 511–520 (2002).
   PubMedGoogle Scholar
• Carral F, Oliveira G, Salas J, García I, Sillero A, Aguilar M. Care resource utilization and direct costs incurred by people with diabetes in Spanish hospital. Diabetes Res. Clin. Pract.56, 27–34 (2002).
   PubMed Web of Science ®Google Scholar
• Carral F, Aguilar M, Olveira G, Mangas A, Doménech I, Torres I. Increased hospital expenditures in diabetic patients hospitalized for cardiovascular disease. J. Diabetes Complicat.17, 331–336 (2003).
   PubMed Web of Science ®Google Scholar
• Gisbert R, Brosa M. Health costs database. Soikos Barcelona, Spain (2004).
   Google Scholar
• Aguilar M, Ballesta M, Carral F; Grupo de Diabetes de la SAEN. Indirect costs in Type 2 diabetes mellitus. Endocrinologia y Nutrición49, 59–69 (2002).
   Google Scholar
• Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J. Diabetes Complicat.18, 60–68 (2004).
   PubMed Web of Science ®Google Scholar
• Boyle PJ, Zreblec J. Physiological and behavioral aspects of glycemic control and hypoglycemia in diabetes. South Med. J.100, 175–182 (2007).
   PubMed Web of Science ®Google Scholar
• López Bastida J, Serrano P, Duque B. Los costes socioeconomicos de la diabetes mellitus. Atención Primaria29, 145–150 (2002).
   PubMedGoogle Scholar
• Leiter LA, Yale JF, Chiasson JL, Harris SB, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycaemia episodes on glycemic and hypoglycemia management. Can. J. Diabetes29(3), 186–192 (2005).
   Google Scholar
• Hammer M, Lammert M, Monereo Mejias S, Kern W, Frier BM. Cost of managing severe hypoglycaemia in three European countries. J. Med. Econ.12(4), 281–290 (2009).
   PubMedGoogle Scholar
• Guisasola FA, Casal Llorente C, Rubio-Terrés C. Cost analysis of Type 2 diabetes mellitus treatment with glargine insulin or detemir insulin in Spain. Rev. Esp. Econ. Salud.6(4), 37–43 (2007).
   Google Scholar
• Landkvist J, Berne C, Bobader B, Joasson L. The economic and quality of life impact of hypoglycaemia. Eur. Health Econ.50, 197–202 (2005).
   Google Scholar
• UKPDS 37. Quality of life in Type 2 diabetes is affected by complications not by intensive policies to improve blood glucose or blood pressure control. Diabetes Care22, 1125–1136 (1999).
   PubMed Web of Science ®Google Scholar
• Lammert M, Hammer M, Frier BM. Management of severe hypoglycaemia: cultural similarities, differences and resource consumption in three European countries. J. Med. Econ.12(4), 269–280 (2009).
   PubMedGoogle Scholar
• Polonsky WH, Davis CL, Jacobson AM. Correlates of hypoglycaemia fear in Type I and Type II diabetes mellitus. Health Psychol.11, 199–202 (1992).
   PubMed Web of Science ®Google Scholar
• Strachan MJ. Fear of diabetes complications. Diabetes Metab. Res.21, 262–263 (2005).
   Google Scholar
• Shiu AT, Wong RY. Fears and worries associated with hypoglycaemia and diabetics complications: perceptions and experiencies of Hong Kong Chinese clients. J. Adv. Nurs.39, 155–163 (2002).
   PubMed Web of Science ®Google Scholar
• Clar C, Barnard K, Cummins E, Royle P, Waugh N. Self-monitoring of blood glucose in Type 2 diabetes: systematic review. Health Technol. Assess.14(12), 1–140 (2010).
   Web of Science ®Google Scholar
• Weber C, Schneider B, Lodwig V, Holm MV, Nesser K. Cost impact of glucose blood self-monitoring on complications of Type 2 diabetes: a Swiss Perspective (ROSSO Study n 11). Swiss Med. Wkly137, 545–550 (2007).
   PubMedGoogle Scholar
• Davis WA, Bruce DG, Davis TM. Is self-monitoring of blood glucose appropriate for all Type2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care29(8), 1764–1770 (2006).
   PubMed Web of Science ®Google Scholar
• Tunis SL, Minshall ME. Self-monitoring of blood glucose in Type 2 diabetes: cost-effectiveness in the United States. Am. J. Manag. Care.14(3), 131–140 (2008).
   PubMed Web of Science ®Google Scholar
• Farmer AJ, Wade AN, French DP et al. Blood glucose self-monitoring in Type 2 diabetes: a randomised controlled trial. Health Technol. Assess.13(15), iii–iv, ix–xi, 1–50 (2009).
   PubMed Web of Science ®Google Scholar
• Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight Type 2 diabetic patients. Acta Diabetol.31, 215–219 (1994).
   PubMed Web of Science ®Google Scholar
• Klonoff DC. New evidence demonstrates that self-monitoring of blood glucose does not improve outcomes in Type 2 diabetes – when this practice is not applied properly. J. Diabetes Sci. Technol.2(3), 342–348 (2008).
   PubMedGoogle Scholar
• Franciosi M, Pellegrini F, De Berardis G et al. The impact of blood glucose self-monitoring on metabolic control and quality of life in Type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care24, 1870–1877 (2001).
   PubMed Web of Science ®Google Scholar
• Norfeldt S, Ludvigsson J. Fear and other disturbances of severe hypoglycaemia in children and adolescents with Type 1 diabetes mellitus. J. Ped. Endo. Metab.18, 83–91 (2005).
   PubMedGoogle Scholar
• Internacional Organization for Standarization. In vitro diagnostic test systems-requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. In: ISO Report 15197. Internacional Organization for Standarization, Geneva, Switzerland (2003).
   Google Scholar
• Sheffield CA, Kane MP, Bakst G, Busch RS, Abelseth JM, Hamilton RA. Accuracy and precision of four value-added blood glucose meters: the Abbott Optium, the DDI Prodigy, the HDI True Track, and the HypoGuard Assure Pro. Diabetes Technol. Ther.11(9), 587–592 (2009).
   PubMedGoogle Scholar
• Ginsberg BH. Factors affecting blood glucose monitoring: sources of errors in measurement. J. Diabetes Sci. Technol.3(4), 903–913 (2009).
   PubMedGoogle Scholar
• Neeser K, Weber C. Cost impact of self-monitoring of blood glucose on complications of Type 2 diabetes: the Spanish perspective. Diabetes Technol. Ther.11(8), 509–511 (2009).
   PubMedGoogle Scholar
• Tunis SL, Willis WD, Foos V. Self-monitoring of blood glucose (SMBG) in patients with Type 2 diabetes on oral anti-diabetes drugs: cost–effectiveness in France, Germany, Italy, and Spain. Curr. Med. Res. Opin.26, 163–175 (2010).
   PubMed Web of Science ®Google Scholar